Granted Patent B2

US 10,471,067 · App. 15/437,534 · Granted Nov 12, 2019

Inventors: Eugene R. Cooper (Berwyn, PA); Tuula Ryde (Malvern, PA); John Pruitt (Suwanee, GA); Laura Kline (Harleysville, PA)

Assignee: Recro Pharma, Inc.

A61K31/5415A61K9/0019A61K9/0053A61K9/10A61K9/14A61K9/145A61K9/146A61K9/5123A61K9/5138A61K9/5169A61K9/5192

Abstract

Claims (19)

1. An injectable pharmaceutical dosage form comprising:

30 mg of meloxicam, or a salt thereof, wherein the meloxicam is in the form of particles having an effective average particle size of less than or about 2000 nm;

polyvinylpyrrolidone;

sodium deoxycholate;

sucrose; and

water;

wherein the dosage form does not comprise a combination of meloxicam and a vasomodulator.

2. The dosage form of claim 1 , wherein the effective average particle size of the meloxicam particles, or a salt thereof, is less than about 1500 nm, less than about 1000 nm, less than about 900 nm, less than about 800 nm, less than about 700 nm, less than about 600 nm, less than about 500 nm, less than about 400 nm, less than about 300 nm, less than about 250 nm, less than about 200 nm, less than about 150 nm, less than about 100 nm, less than about 75 nm, or less than about 50 nm.

3. The dosage form of claim 1 , wherein the effective average particle size of the meloxicam particles, or a salt thereof, is about 1500 nm, about 1000 nm, about 900 nm, about 800 nm, about 700 nm, about 600 nm, about 500 nm, about 400 nm, about 300 nm, about 250 nm, about 200 nm, about 150 nm, about 100 nm, about 75 nm, or about 50 nm.

4. The dosage form of claim 1 , wherein the dosage form further comprises one or more non-meloxicam active agents, wherein the non-meloxicam active agent is not a vasomodulator.

5. A method of administering meloxicam to a human in need thereof comprising intravenously or intramuscularly injecting the dosage form of claim 1 into the human.

6. An injectable pharmaceutical dosage form consisting essentially of:

30 mg of meloxicam, or a salt thereof, wherein the meloxicam is in the form of particles having an effective average particle size of less than about 400 nm;

polyvinylpyrrolidone;

sodium deoxycholate;

sucrose; and

water.

7. The dosage form of claim 6 , wherein the effective average particle size of the meloxicam particles, or a salt thereof, is less than about 1500 nm, less than about 1000 nm, less than about 900 nm, less than about 800 nm, less than about 700 nm, less than about 600 nm, less than about 500 nm, less than about 400 nm, less than about 300 nm, less than about 250 nm, less than about 200 nm, less than about 150 nm, less than about 100 nm, less than about 75 nm, or less than about 50 nm.

8. The dosage form of claim 6 , wherein the effective average particle size of the meloxicam particles, or a salt thereof, is about 1500 nm, about 1000 nm, about 900 nm, about 800 nm, about 700 nm, about 600 nm, about 500 nm, about 400 nm, about 300 nm, about 250 nm, about 200 nm, about 150 nm, about 100 nm, about 75 nm, or about 50 nm.

Assignments (17)

Continuity (5)